Search results
Page 1 of 543
Reply To: Cytopenias/lack of response with generic imatinib
HI Lindi We haven’t experienced cytopenias that I have noticed (though I haven’t really looked…) however, we do see patients unable to tolerate some generic imatinib preps in terms of…
30/07/2025
Cytopenias/lack of response with generic imatinib
Has anyone else had reports from their haematology team, or noticed themselves, that patients are either not responding to generic imatinib tablets or are experiencing cytopenias with the generics? Our…
Specialist Clinical Trials Pharmacist (Oncology/Haematology) – SCRI- London
We are looking for a Specialist Clinical Trials Pharmacist with Oncology/Haematology experience to join our team at Sarah Cannon Research Institute in London. This is a Band 7/8a post depending…
ISOPP July 2025 Newsletter
Volume 27 | No.7 | July 2025 From Netty Cracknell, ISOPP President Dear BOPA members, This month has been incredibly busy, and while there are moments I feel completely exhausted,…
29/07/2025
Syringe interpolation / graduation interpretation
Hi, What is everyone’s opinion on syringe interpolation i.e. how would you go about making 1400mg/11.7ml s/c rituximab? I wrote a document to convince my team but they aren’t convinced.
28/07/2025
Reply To: Set up of Nivolumab- Relatlimab on ChemoCare and CMM?
I know this is overdue but we had similar problems. I wasn’t personally involved with setting this one up but I did pass comment when it first presented itself. We…
Reply To: BOPA Executive TCON – August 2025
Hope you’re well. Just sending a quick email after our last E&T meeting to raise the potential for a BOPA position statement/guideline on GLP-1 agents and cancer. This is just…
Page 1 of 543